PrECOG PrE0807:纳武利尤单抗单用及联合利瑞鲁单抗新辅助治疗不适合或拒绝顺铂化疗的肌层浸润性膀胱癌患者的1b期可行性试验
这项1b期试验纳入43例不适合或拒绝顺铂新辅助化疗的肌层浸润性膀胱癌患者,术前接受两剂纳武利尤单抗单用(队列1,n=13)或联合利瑞鲁单抗(队列2,n=30)。主要终点为≥3级治疗相关不良事件发生率,队列1为0%(90%CI 0-21%),队列2为7%(90%CI 1-20%),均未发生4/5级事件;结论认为该方案安全、可行且耐受良好,但ypT0N0率低于预期,2年生存率似乎与其他新辅助免疫治疗试验相当。
要点
- 43例患者中41例行根治性膀胱切除术,末次给药至手术中位时间4周,无患者手术延迟超过6周。
- 队列1和队列2的ypT0N0率分别为17%和21%,<ypT2N0率分别为25%和32%。
- 队列1和队列2的2年无复发生存率分别为73%和71%,2年总生存率分别为82%和89%。
核心结论
- 新辅助纳武利尤单抗为基础的免疫治疗在不适合顺铂的肌层浸润性膀胱癌患者中安全、可行且耐受良好。
- ypT0N0率低于预期,但2年生存率似乎与其他新辅助免疫治疗试验相当。
- 纳武利尤单抗正在CA-017-078试验(NCT03661320)中接受评估。
研究设计与样本
- 1b期可行性试验(NCT03532451),患者接受两剂纳武利尤单抗480 mg单用(队列1)或联合利瑞鲁单抗240 mg(队列2)后行根治性膀胱切除术,队列序贯入组。
- 关键入组标准为cT2-4aN0-1M0分期且不适合或拒绝顺铂化疗。
- 主要终点为根据不良事件通用术语标准5.0版判定的≥3级治疗相关不良事件发生率。
- 关键次要终点包括末次给药后超过6周行根治性膀胱切除术的患者比例、治疗前经尿道膀胱肿瘤电切术与治疗后根治性膀胱切除术之间CD8+ T细胞密度变化、ypT0N0率、<ypT2N0率、2年无复发生存率和总生存率。
- 共入组43例患者(队列1 n=13,队列2 n=30)。
主要发现
- 队列1和队列2分别有13例和29例完成计划新辅助治疗,41例行根治性膀胱切除术。
- 末次给药至根治性膀胱切除术的中位时间为4周。
- 3级治疗相关不良事件发生率在队列1为0%(90%CI 0-21%),在队列2为7%(90%CI 1-20%);所有事件均缓解,未发生4/5级治疗相关不良事件。
- 无患者根治性膀胱切除术延迟超过6周。
- 在行根治性膀胱切除术的肌层浸润性膀胱癌患者中,队列1和队列2的ypT0N0率分别为17%和21%,<ypT2N0率分别为25%和32%,2年无复发生存率分别为73%和71%,2年总生存率分别为82%和89%。
关键数值与推荐
- 3级治疗相关不良事件发生率:队列1为0%(90%CI 0-21%),队列2为7%(90%CI 1-20%)。
- ypT0N0率:队列1为17%,队列2为21%。
- <ypT2N0率:队列1为25%,队列2为32%。
- 2年无复发生存率:队列1为73%,队列2为71%。
- 2年总生存率:队列1为82%,队列2为89%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Neoadjuvant cisplatin-based chemotherapy prior to radical cystectomy (RC) improves overall survival (OS) in muscle-invasive bladder cancer (MIBC). However, many patients are cisplatin ineligible; therefore, new treatment options are needed. Nivolumab without/with lirilumab prior to RC was investigated in cisplatin-ineligible patients in this phase 1b trial (NCT03532451) to determine its safety/feasibility. METHODS: Patients with localized MIBC received two doses of nivolumab (480 mg) alone (cohort 1) or with lirilumab (240 mg; cohort 2) prior to RC. Cohorts were enrolled sequentially. The key eligibility criteria were cT2-4aN0-1M0 stage and cisplatin ineligibility/refusal. The primary endpoint was the rate of grade (G) ≥3 treatment-related adverse events (TRAEs) as per Common Terminology Criteria for Adverse Events version 5.0. The key secondary endpoints included the proportion of patients who underwent RC >6 wk after the last dose, CD8+ T-cell density change between pretreatment transurethral resection of bladder tumor (TURBT) and post-treatment RC, ypT0N0, <ypT2N0 rates, 2-yr recurrence-free survival (RFS), and OS. KEY FINDINGS AND LIMITATIONS: Among 43 patients enrolled (n = 13, cohort 1; n = 30, cohort 2), 13 and 29 completed intended neoadjuvant therapy, respectively, in cohorts 1 and 2, and 41 underwent RC. The median time from the last dose to RC was 4 wk. The G3 TRAEs occurred in 0% (90% confidence interval [CI] 0-21%) of patients in cohort 1 and 7% (90% CI 1-20%) in cohort 2; all these TRAEs resolved and no G4/5 TRAEs occurred. No patient had delayed RC for >6 wk. In cohorts 1 and 2, ypT0N0 rates for patients with MIBC and RC were 17% and 21%, <ypT2N0 rates were 25% and 32%, 2-yr RFS rates were 73% and 71%, and 2-yr OS rates were 82% and 89%, respectively. CD8+ T-cell density increased significantly from TURBT to RC in cohort 2. CONCLUSIONS AND CLINICAL IMPLICATIONS: Neoadjuvant nivolumab-based immunotherapy was safe, feasible, and well tolerated in cisplatin-ineligible patients with MIBC. Although ypT0N0 rates were lower than expected, 2-yr survival rates seem to be comparable with those of other neoadjuvant immunotherapy trials. Nivolumab is being evaluated in the CA-017-078 trial (NCT03661320). PATIENT SUMMARY: For patients with muscle-invasive bladder cancer unable to receive cisplatin-based chemotherapy, treatment with nivolumab without and with lirilumab prior to radical cystectomy was safe, feasible, and well tolerated. Nivolumab-based immunotherapy showed lower pathologic response rates than but similar survival rates to other neoadjuvant immunotherapy trials.
引用
- Grivas P, Koshkin VS, Chu X, et al. PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant Chemotherapy. Eur Urol Oncol. 2023. PMID: 38155060. doi:10.1016/j.euo.2023.11.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。